Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
NBIX [NASD]
Neurocrine Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E22.45 EPS (ttm)4.16 Insider Own1.30% Shs Outstand93.40M Perf Week-4.92%
Market Cap8.71B Forward P/E19.67 EPS next Y4.75 Insider Trans-27.86% Shs Float91.22M Perf Month2.83%
Income407.30M PEG0.68 EPS next Q0.55 Inst Own97.00% Short Float4.88% Perf Quarter-9.21%
Sales1.05B P/S8.33 EPS this Y977.20% Inst Trans0.07% Short Ratio3.61 Perf Half Y-8.35%
Book/sh12.06 P/B7.74 EPS next Y54.95% ROA26.60% Target Price128.05 Perf Year-2.79%
Cash/sh8.59 P/C10.87 EPS next 5Y33.20% ROE47.10% 52W Range86.02 - 136.26 Perf YTD-2.61%
Dividend- P/FCF40.02 EPS past 5Y42.90% ROI30.80% 52W High-32.53% Beta0.78
Dividend %- Quick Ratio5.30 Sales past 5Y121.20% Gross Margin99.00% 52W Low6.88% ATR4.03
Employees845 Current Ratio5.40 Sales Q/Q1.60% Oper. Margin13.80% RSI (14)42.63 Volatility3.02% 3.90%
OptionableYes Debt/Eq0.28 EPS Q/Q923.60% Profit Margin38.90% Rel Volume0.76 Prev Close93.35
ShortableYes LT Debt/Eq0.28 EarningsFeb 04 AMC Payout0.00% Avg Volume1.23M Price91.94
Recom2.00 SMA20-2.75% SMA50-10.14% SMA200-13.20% Volume340,912 Change-1.51%
Feb-02-21Initiated Raymond James Outperform $163
Sep-30-20Initiated The Benchmark Company Hold
Aug-04-20Downgrade JP Morgan Overweight → Neutral $136
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Apr-08-21 04:01PM  
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
PR Newswire
Mar-26-21 09:33AM  
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?
Zacks
Mar-25-21 04:01PM  
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day
PR Newswire +11.07%
03:34PM  
Why Neurocrine Biosciences Stock Jumped Today
Motley Fool
Mar-24-21 06:35PM  
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600
PR Newswire
Mar-22-21 07:21AM  
Introducing Neurocrine Biosciences (NASDAQ:NBIX), The Stock That Zoomed 161% In The Last Five Years
Simply Wall St.
Mar-20-21 11:00AM  
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021
PR Newswire
Mar-18-21 06:02PM  
Top Biotech Stocks for Q2 2021
Investopedia
Mar-09-21 04:01PM  
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference
PR Newswire
Mar-02-21 08:53AM  
Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity
Benzinga -7.32%
07:30AM  
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
PR Newswire
Feb-23-21 04:01PM  
Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference
PR Newswire
Feb-04-21 11:31PM  
Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcript
Motley Fool
05:55PM  
Neurocrine Biosciences (NBIX) Q4 Earnings Top Estimates
Zacks
04:49PM  
Recap: Neurocrine Biosciences Q4 Earnings
Benzinga
04:01PM  
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
PR Newswire
02:45PM  
Neurocrine Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
04:00AM  
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Latest Stock Performance A Reflection Of Its Financial Health?
Simply Wall St.
Feb-02-21 04:01PM  
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
GlobeNewswire +7.00%
Jan-28-21 12:32PM  
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Zacks
Jan-20-21 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
PR Newswire
Jan-08-21 10:15AM  
Neurocrine Biosciences Shares Rise Despite Disappointing Q4 Earnings; Target Price $121
FX Empire +9.00%
07:30AM  
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
PR Newswire
Jan-04-21 04:01PM  
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-22-20 04:17PM  
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
GlobeNewswire
Dec-21-20 11:36AM  
Is NBIX A Good Stock To Buy Now?
Insider Monkey
04:22AM  
Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today?
Simply Wall St.
Dec-11-20 08:58AM  
Is Neurocrine Biosciences (NBIX) a Smart Long-term Buy?
Insider Monkey
Dec-09-20 07:51AM  
New Strong Sell Stocks for December 9th
Zacks
Nov-19-20 09:00AM  
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
08:00AM  
Neurocrine Biosciences Announces Repurchase of Convertible Notes
PR Newswire
Nov-13-20 07:29AM  
Results: Neurocrine Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Simply Wall St.
Nov-10-20 04:00PM  
Neurocrine Biosciences Inc (NBIX) Q3 2020 Earnings Call Transcript
Motley Fool -14.81%
Nov-09-20 05:15PM  
Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue Estimates
Zacks +6.72%
04:54PM  
Recap: Neurocrine Biosciences Q3 Earnings
Benzinga
04:01PM  
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results
PR Newswire
02:45PM  
Neurocrine Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
09:00AM  
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
Nov-06-20 10:18AM  
Preview: Neurocrine Biosciences's Earnings
Benzinga
Nov-04-20 11:10AM  
Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)?
Insider Monkey +13.00%
Nov-02-20 12:31PM  
Earnings Preview: Neurocrine Biosciences (NBIX) Q3 Earnings Expected to Decline
Zacks
11:45AM  
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
Zacks
Oct-19-20 07:56AM  
New Strong Sell Stocks for October 19th
Zacks
Oct-15-20 10:45AM  
Is Neurocrine Biosciences (NASDAQ:NBIX) Using Too Much Debt?
Simply Wall St.
Oct-08-20 08:00AM  
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
GlobeNewswire
Oct-07-20 06:45AM  
Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic
PR Newswire
Oct-06-20 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
PR Newswire
Sep-30-20 09:35AM  
Benzinga's Top Upgrades, Downgrades For September 30, 2020
Benzinga
Sep-28-20 04:01PM  
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting
PR Newswire
Sep-14-20 01:24PM  
Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug
Motley Fool +5.62%
08:43AM  
Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
PR Newswire
08:30AM  
Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease
Reuters
Sep-11-20 03:27PM  
Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy
Motley Fool
11:36AM  
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinsons Disease
GlobeNewswire
11:34AM  
Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020
PR Newswire
11:32AM  
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease
PR Newswire
Sep-09-20 09:48PM  
Neurocrine Biosciences (NBIX): Hedge Funds In Wait-and-See Mode
Insider Monkey
03:12PM  
Neurocrine Biosciences (NASDAQ:NBIX) Shareholders Have Enjoyed An Impressive 102% Share Price Gain
Simply Wall St.
Sep-08-20 04:01PM  
Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
PR Newswire
Sep-03-20 04:06PM  
Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings
PR Newswire
Sep-02-20 04:01PM  
Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference
PR Newswire
Aug-28-20 10:11AM  
Looking Into Neurocrine Biosciences's Return On Capital Employed
Benzinga
Aug-04-20 09:30AM  
Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
Motley Fool
08:38AM  
How Is Neurocrine Biosciences' (NASDAQ:NBIX) CEO Paid Relative To Peers?
Simply Wall St.
06:34AM  
How Neurocrine Biosciences Crushed It in Q2
Motley Fool
Aug-03-20 05:15PM  
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Zacks
04:37PM  
Neurocrine Biosciences Stock Pops After Earnings Double, Shatter Views
Investor's Business Daily
04:01PM  
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
PR Newswire
Jul-30-20 04:01PM  
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020
PR Newswire
Jul-27-20 12:31PM  
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
Jul-13-20 07:16PM  
Did Hedge Funds Make The Right Call On Neurocrine Biosciences, Inc. (NBIX)?
Insider Monkey
04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
PR Newswire
Jul-01-20 07:00AM  
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
Reuters
Jun-25-20 12:17PM  
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
Zacks
Jun-17-20 04:04PM  
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
GuruFocus.com
Jun-16-20 07:00AM  
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
Business Wire
Jun-15-20 04:01PM  
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
PR Newswire
Jun-08-20 11:01AM  
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
PR Newswire
Jun-05-20 11:26AM  
Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
Investor's Business Daily
Jun-04-20 04:01PM  
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
PR Newswire
Jun-03-20 01:44AM  
Edited Transcript of NBIX earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents
Jun-01-20 11:46AM  
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
Zacks
May-29-20 04:13PM  
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
PR Newswire
May-26-20 04:01PM  
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
PR Newswire
09:39AM  
Are Investors Undervaluing Neurocrine Biosciences, Inc. (NASDAQ:NBIX) By 33%?
Simply Wall St.
May-23-20 08:00AM  
Teladoc, Neurocrine Bio Lead Five Healthy Stocks To Monitor Closely
Investor's Business Daily
May-18-20 12:16PM  
Neurocrine Biosciences Soars Into Buy Zone
Investor's Business Daily Video +6.79%
May-14-20 07:29PM  
Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference
PR Newswire
06:27AM  
Is Now a Good Time To Buy Neurocrine Biosciences?
Motley Fool
May-13-20 04:01PM  
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
PR Newswire
02:58PM  
The Top 10 Stocks of the Past Decade
Kiplinger
02:38PM  
IBD 50 Stocks To Watch: Top Biotech Scores Price-Target Hikes As It Nears Buy Point
Investor's Business Daily
May-12-20 04:55PM  
This IBD Stock Of The Day Is Setting Up After A Bullish First-Quarter Report
Investor's Business Daily
May-11-20 04:01PM  
Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy
PR Newswire
May-07-20 08:09PM  
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
Motley Fool +5.28%
05:30PM  
Neurocrine Biosciences Inc (NBIX) Q1 2020 Earnings Call Transcript
Motley Fool
04:01PM  
Neurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders
PR Newswire
May-06-20 05:35PM  
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Top Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
PR Newswire
May-05-20 04:01PM  
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020
PR Newswire
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for the treatment of rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for the treatment of anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL A Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise35.991,70061,18333,610Feb 12 08:27 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale119.961,700203,92632,510Feb 12 08:27 PM
Lippoldt DarinChief Legal OfficerFeb 09Option Exercise35.9936,1941,302,62264,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 09Sale116.1736,1944,204,83134,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 08Sale116.723,407397,67431,914Feb 09 09:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 08Sale116.7510,4661,221,864446,144Feb 09 09:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 08Sale116.692,708315,99983,456Feb 09 09:18 PM
ROBERTS EIRYChief Medical OfficerFeb 08Sale116.782,363275,94417,231Feb 09 09:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 08Sale116.813,261380,92930,437Feb 09 09:20 PM
Cooke JulieChief Human Resources OfficerFeb 08Sale116.731,338156,18912,915Feb 09 09:24 PM
BENEVICH ERICChief Commercial OfficerFeb 08Sale116.824,270498,84218,018Feb 09 09:26 PM
ABERNETHY MATTChief Financial OfficerFeb 08Sale116.822,910339,94213,043Feb 09 09:30 PM
Bozigian Haig P.Chief Development OfficerFeb 08Sale116.803,842448,749154,934Feb 09 09:27 PM
Gano KyleChief Business Development OffFeb 08Sale116.853,693431,518102,406Feb 09 09:42 PM
Gano KyleChief Business Development OffFeb 05Sale114.002,677305,18498,663Feb 09 09:42 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale113.7970480,109153,328Feb 09 09:27 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale114.0380992,24716,434Feb 09 09:26 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale113.8660568,88612,125Feb 09 09:24 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale114.1586598,73929,675Feb 09 09:20 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale113.7660568,82382,169Feb 09 09:18 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale114.162,422276,504443,249Feb 09 09:17 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale114.0560569,00330,627Feb 09 09:16 PM
BENEVICH ERICChief Commercial OfficerJan 26Option Exercise41.7830012,53416,105Jan 27 08:58 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Option Exercise35.991,10039,58929,602Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 26Sale120.0040048,00015,705Jan 27 08:58 PM
LYONS GARY ADirectorJan 26Sale120.0040048,000223,697Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Sale119.971,100131,96529,002Jan 27 09:30 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Option Exercise34.4617,570605,47037,960Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 25Option Exercise41.783,477145,26920,882Jan 27 08:58 PM
BENEVICH ERICChief Commercial OfficerJan 25Sale120.035,077609,37115,805Jan 27 08:58 PM
LYONS GARY ADirectorJan 25Sale120.031,600192,047224,097Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Sale119.9717,5702,107,81229,002Jan 27 09:30 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 08Option Exercise8.65308,2502,667,797605,872Jan 12 04:16 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale111.062,632292,29715,845Jan 12 04:17 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 08Sale110.22308,25033,973,877441,071Jan 12 04:16 PM
ABERNETHY MATTChief Financial OfficerDec 01Sale94.661,645155,72111,494Dec 02 04:12 PM
BENEVICH ERICChief Commercial OfficerNov 12Sale90.712,257204,72317,405Nov 16 06:27 PM
ROBERTS EIRYChief Medical OfficerNov 12Sale90.742,257204,81013,477Nov 16 06:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 12Sale90.732,257204,77629,002Nov 16 06:21 PM
Lippoldt DarinChief Legal OfficerNov 12Sale90.722,257204,75530,082Nov 16 06:20 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 12Sale90.732,257204,78481,624Nov 16 06:19 PM
GORMAN KEVIN CHARLESChief Executive OfficerNov 12Sale90.783,390307,748441,071Nov 16 06:16 PM
Gano KyleChief Business Development OffNov 12Sale90.732,257204,77098,028Nov 16 06:11 PM
Cooke JulieChief Human Resources OfficerNov 12Sale90.732,257204,77811,580Nov 16 06:10 PM
Bozigian Haig P.Chief Development OfficerNov 12Sale90.742,257204,806152,694Nov 16 06:08 PM
ABERNETHY MATTChief Financial OfficerNov 12Sale90.742,257204,81010,014Nov 16 06:02 PM
BENEVICH ERICChief Commercial OfficerNov 02Option Exercise35.9920,595741,21435,969Nov 04 06:09 PM
BENEVICH ERICChief Commercial OfficerNov 02Sale96.5320,5951,987,97215,374Nov 04 06:09 PM
Cooke JulieChief Human Resources OfficerOct 02Sale95.2698794,0229,549Oct 06 04:05 PM
ROBERTS EIRYChief Medical OfficerAug 05Sale118.842,257268,22511,446Aug 07 07:51 PM
Lloyd-Smith MalcolmChief Regulatory OfficerAug 05Sale118.862,257268,27726,971Aug 07 07:47 PM
Lippoldt DarinChief Legal OfficerAug 05Sale118.872,257268,29728,051Aug 07 07:40 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 05Sale118.832,257268,20079,593Aug 07 07:36 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 05Sale118.913,390403,101438,021Aug 07 07:29 PM
Gano KyleChief Business Development OffAug 05Sale118.872,257268,28695,997Aug 07 07:24 PM
Cooke JulieChief Human Resources OfficerAug 05Sale118.912,257268,3838,661Aug 07 07:21 PM
Bozigian Haig P.Chief Development OfficerAug 05Sale118.892,257268,324150,663Aug 07 07:14 PM
BENEVICH ERICChief Commercial OfficerAug 05Sale118.852,257268,25415,374Aug 07 06:35 PM
ABERNETHY MATTChief Financial OfficerAug 05Sale118.902,257268,3567,983Aug 07 06:22 PM
Lippoldt DarinChief Legal OfficerJul 09Option Exercise35.991,65759,63527,678Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJul 09Sale136.021,657225,38626,021Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJun 23Option Exercise32.995,000164,95031,021Jun 25 04:15 PM
ROBERTS EIRYChief Medical OfficerJun 23Option Exercise77.815,000389,05014,416Jun 25 04:19 PM
ROBERTS EIRYChief Medical OfficerJun 23Sale130.005,000650,0009,416Jun 25 04:19 PM
Lippoldt DarinChief Legal OfficerJun 23Sale130.005,000650,00026,021Jun 25 04:15 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 11Option Exercise35.905,571199,97677,563Jun 15 05:31 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Sale126.5542,7495,409,93371,992May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise32.995,000164,95031,021May 20 07:15 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Sale119.9810,0001,199,800104,741May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Sale120.005,000600,00026,021May 20 07:15 PM
Bozigian Haig P.Chief Development OfficerMay 12Option Exercise63.1061,5553,884,054167,204May 14 08:09 PM
Bozigian Haig P.Chief Development OfficerMay 12Sale114.9461,5557,075,396148,633May 14 08:09 PM
ABERNETHY MATTChief Financial OfficerMay 07Option Exercise73.6015,0001,104,00020,953May 11 08:17 PM
ABERNETHY MATTChief Financial OfficerMay 07Sale110.2115,0001,653,1345,953May 11 08:17 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 07Sale105.448,682915,454104,741May 11 08:06 PM
SHERWIN STEPHEN ADirectorApr 28Sale99.3917,6871,757,96629,861Apr 30 04:27 PM
ABERNETHY MATTChief Financial OfficerApr 28Sale102.491,741178,4355,953Apr 30 04:25 PM
GORMAN KEVIN CHARLESChief Executive OfficerApr 24Sale99.452,906289,016434,971Apr 28 08:41 PM
Gano KyleChief Business Development OffApr 24Sale99.471,934192,37793,967Apr 28 08:40 PM
Cooke JulieChief Human Resources OfficerApr 24Sale99.461,934192,3646,631Apr 28 08:38 PM
Bozigian Haig P.Chief Development OfficerApr 24Sale99.461,934192,351148,633Apr 28 08:35 PM
BENEVICH ERICChief Commercial OfficerApr 24Sale99.451,934192,33813,344Apr 28 08:33 PM
ABERNETHY MATTChief Financial OfficerApr 24Sale99.521,934192,4677,694Apr 28 08:32 PM
ROBERTS EIRYChief Medical OfficerApr 24Sale99.471,934192,3769,416Apr 28 08:46 PM
Lloyd-Smith MalcolmChief Regulatory OfficerApr 24Sale99.451,934192,32924,941Apr 28 08:44 PM
Lippoldt DarinChief Legal OfficerApr 24Sale99.491,934192,41626,021Apr 28 08:43 PM
Grigoriadis Dimitri E.Chief Research OfficerApr 24Sale99.411,934192,258113,423Apr 28 08:42 PM
BENEVICH ERICChief Commercial OfficerApr 15Sale94.658,632817,01811,603Apr 17 09:48 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.